Hepatic O2 exchange and liver energy metabolism in hyperdynamic porcine endotoxemia: effects of iloprost

Intensive Care Med. 2000 Oct;26(10):1531-9. doi: 10.1007/s001340000645.

Abstract

Objective: To compare the effects of a 12 h continuous infusion of iloprost, a stable prostacyclin analogue, on hepatic blood flow (Qliv), O2 exchange, and energy metabolism during a 24 h hyperdynamic, porcine endotoxemia with volume resuscitation alone.

Design: Prospective, randomized, experimental study with repeated measures.

Setting: Investigational animal laboratory.

Subjects: Twenty-eight domestic pigs: 16 animals during endotoxemia with volume resuscitation alone (ETX), 12 with endotoxemia, volume resuscitation, and treatment with iloprost (ILO).

Interventions: Endotoxemia was initiated by continuous infusion of E. coli lipopolysaccharide. Animals were resuscitated with hetastarch, aimed at maintaining a MAP of > 60 mmHg. After 12 h of endotoxemia, iloprost was administered for 12 h in the treatment group, titrated to avoid pharmacologically induced hypotension (MAP < 60 mmHg).

Measurements and results: Iloprost significantly increased Qliv, with no effect on hepatic O2 delivery. Mean capillary hemoglobin O2 saturation (HbScO2) on the liver surface, as well as HbScO2 frequency distributions--a measure of microcirculatory O2 availability--remained unchanged. Treatment with iloprost, however, significantly attenuated the endotoxin-induced derangements of cellular energy metabolism as reflected by the diminished progressive decrease in hepatic lactate uptake rate and a blunted increase in hepatic venous lactate/pyruvate ratios. While endotoxin significantly increased endogenous glucose production (EGP) rate, iloprost restored EGP to normal at the end of the experiment.

Conclusions: Thus, in a clinically relevant model of human sepsis, iloprost did not produce potential adverse effects but rather ameliorated hepatic metabolic disturbances and, thereby, hepatic energy balance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Gas Analysis
  • Disease Models, Animal*
  • Drug Evaluation, Preclinical
  • Endotoxemia / drug therapy*
  • Endotoxemia / metabolism*
  • Endotoxemia / microbiology
  • Endotoxemia / physiopathology
  • Energy Metabolism / drug effects*
  • Escherichia coli
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / metabolism*
  • Escherichia coli Infections / microbiology
  • Escherichia coli Infections / physiopathology
  • Female
  • Fluid Therapy / methods
  • Hemodynamics / drug effects
  • Hemoglobins / analysis
  • Iloprost / pharmacology
  • Iloprost / therapeutic use*
  • Lactic Acid / metabolism
  • Lipopolysaccharides
  • Liver / blood supply
  • Liver / drug effects*
  • Liver / metabolism*
  • Male
  • Microcirculation / drug effects
  • Oxygen Consumption / drug effects*
  • Prospective Studies
  • Pyruvic Acid / metabolism
  • Random Allocation
  • Resuscitation / methods
  • Swine
  • Time Factors
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use*

Substances

  • Hemoglobins
  • Lipopolysaccharides
  • Vasodilator Agents
  • Lactic Acid
  • Pyruvic Acid
  • Iloprost